Pluristem Therapeutics

Pluri's business is centered on its advanced, three-dimensional (3D) cell expansion technology platform. This system is designed for the mass production of high-quality cells in a scalable and cost-effective manner, maintaining batch-to-batch consistency. The company's initial focus was on developing placental expanded (PLX) cell therapy products. PLX cells are derived from placentas and are allogeneic, meaning they do not require tissue or genetic matching before administration to a patient. These cells release therapeutic proteins that can help the body's own regenerative mechanisms to heal damaged tissues. The company's pipeline included PLX-PAD for conditions like muscle injury and PLX-R18 for hematological disorders and acute radiation syndrome.

Recognizing the broader potential of its cell expansion capabilities, Pluri has diversified its operations. The company now operates in the regenerative medicine and food-tech sectors and is pursuing partnerships in agritech and biologics. A significant milestone in this diversification was the January 2022 collaboration with Tnuva, Israel's largest food producer, to create a joint venture called Ever After Foods. This venture aims to develop and manufacture cultured meat products, combining Pluri's cell production expertise with Tnuva's food development and distribution capabilities. Pluri also engages in Contract Development and Manufacturing Organization (CDMO) activities. The company's shares are publicly traded on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol PLUR.